HER2 Support Group Forums - View Single Post - New trial to help healthy women avoid unnecessary breast operations, UK

'lizbeth · 12-10-2013, 09:04 AM

OngoingClinical Trials 2: DCIS OT2-3-01 The LORIS trial: A multicentre, randomized phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ
Francis A, Bartlett JMS, Billingham LJ, Bowden SJ, Brookes CL, Dodwell DJ, Evans AZ, Fallowfield LJ, Gaunt CH, Hanby AM, Jenkins VA, Pinder S, Reed MW, Roberts T, Thomas JS, Wallis MG, Wilcox MH, Rea DW. Queen Elizabeth Hospital, Birmingham, United Kingdom; University of Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Dundee, Dundee, United Kingdom; University of Sussex, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; University of Sheffield, Sheffield, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; St. James's Hospital, Leeds, United Kingdom.

OT2-3-02
NSABP B-43: A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx)
Cobleigh MA, Anderson SJ, Juilan TB, Siziopikou KP, Arthur DW, Rabinovitch RA, Zheng P, Mamounas EP, Wolmark N. National Surgical Adjuvant Breast and Bowel Project (NSABP); Rush University; University of Pittsburgh Graduate School of Public Health; Allegheny Cancer Center at Allegheny General Hospital; Northwestern University Feinberg School of Medicine; Virginia Commonwealth University; University of Colorado Denver; MD Anderson Cancer Center, Orlando.

12-10-2013, 09:04 AM	#3
'lizbeth Senior Member Join Date: Apr 2008 Location: Sunny San Diego Posts: 2,214	Re: New trial to help healthy women avoid unnecessary breast operations, UK OngoingClinical Trials 2: DCIS OT2-3-01 The LORIS trial: A multicentre, randomized phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ Francis A, Bartlett JMS, Billingham LJ, Bowden SJ, Brookes CL, Dodwell DJ, Evans AZ, Fallowfield LJ, Gaunt CH, Hanby AM, Jenkins VA, Pinder S, Reed MW, Roberts T, Thomas JS, Wallis MG, Wilcox MH, Rea DW. Queen Elizabeth Hospital, Birmingham, United Kingdom; University of Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Dundee, Dundee, United Kingdom; University of Sussex, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; University of Sheffield, Sheffield, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; St. James's Hospital, Leeds, United Kingdom. OT2-3-02 NSABP B-43: A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx) Cobleigh MA, Anderson SJ, Juilan TB, Siziopikou KP, Arthur DW, Rabinovitch RA, Zheng P, Mamounas EP, Wolmark N. National Surgical Adjuvant Breast and Bowel Project (NSABP); Rush University; University of Pittsburgh Graduate School of Public Health; Allegheny Cancer Center at Allegheny General Hospital; Northwestern University Feinberg School of Medicine; Virginia Commonwealth University; University of Colorado Denver; MD Anderson Cancer Center, Orlando.